You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

MIDAZOLAM - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for midazolam and what is the scope of freedom to operate?

Midazolam is the generic ingredient in nine branded drugs marketed by Exela Pharma, Hikma, Inforlife, Ucb Inc, Apothecon, Baxter Hlthcare Corp, Bedford, Ben Venue, Epic Pharma Llc, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Hospira Inc, Igi Labs Inc, Intl Medicated, Intl Medication, Micro Labs, Pai Holdings, Rising, Steriscience, HLR, Rafa Labs Ltd, MMT, Akorn, Padagis Us, Pharm Assoc, Sun Pharm Inds Ltd, and Roche, and is included in forty-four NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for midazolam. Four suppliers are listed for this compound. There are two tentative approvals for this compound.

Drug Prices for MIDAZOLAM

See drug prices for MIDAZOLAM

Recent Clinical Trials for MIDAZOLAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Abraham NunesPhase 3
Nova Scotia Health AuthorityPhase 3
National Trauma CenterN/A

See all MIDAZOLAM clinical trials

Generic filers with tentative approvals for MIDAZOLAM
Applicant Application No. Strength Dosage Form
⤷  Try a Trial⤷  Try a TrialEQ 5MG BASE/MLINJECTABLE;INJECTION
⤷  Try a Trial⤷  Try a Trial5MGSPRAY;NASAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for MIDAZOLAM
Drug ClassBenzodiazepine
Paragraph IV (Patent) Challenges for MIDAZOLAM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NAYZILAM Nasal Spray midazolam 5 mg/spray 211321 1 2021-06-01

US Patents and Regulatory Information for MIDAZOLAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma MIDAZOLAM HYDROCHLORIDE midazolam hydrochloride INJECTABLE;INJECTION 212847-001 Dec 11, 2020 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hikma MIDAZOLAM HYDROCHLORIDE midazolam hydrochloride INJECTABLE;INJECTION 075243-001 Jun 20, 2000 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Pai Holdings MIDAZOLAM HYDROCHLORIDE midazolam hydrochloride INJECTABLE;INJECTION 078141-001 May 30, 2008 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hikma MIDAZOLAM HYDROCHLORIDE midazolam hydrochloride INJECTABLE;INJECTION 075324-001 Jun 20, 2000 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for MIDAZOLAM

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Neuraxpharm Pharmaceuticals S.L. Buccolam midazolam EMEA/H/C/002267
Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.
Authorised no no no 2011-09-04
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.